There were no fatal treatment-emergent adverse events (TEAEs) in either patient group, but exposure-adjusted incidence rates ...
Daiichi Sankyo showcases strength of industry-leading ADC portfolio with latest research updates from five landmark breast cancer trials at SABCS: Tokyo Tuesday, December 9, 2025, ...
Imagination Technologies made a prominent showing at the 31st ICCAD-Expo 2025 in Chengdu, where strategic partner Xiangdi ...
After 10 years, “Alaska State Troopers” is set to return to television.The show premiered in 2009 and originally aired on ...
After reviewing the positive findings in HER2-positive early-stage breast cancer from both DESTINY-Breast11 (DB-11) and ...
During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...
Tom's Hardware on MSN
Chinese vendor showcases first mass-produced Imagination DXD GPU with ray tracing — sports modern features like super resolution, too
A Chinese vendor has shown what it calls the only mass-produced Imagination DXD-architecture graphics card currently on the ...
Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...
Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...
Congress 2025 took place in Berlin, Germany, a dynamic epicentre known for its blend of innovation, culture, and historical ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
Dr. Charles M. Rudin highlighted new small cell lung cancer therapies, including T cell engagers, antibody-drug conjugates, as well as emerging cell, radiotherapy and combination approaches, during an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback